After all, it is well documented that immune checkpoint blockade treatment has durable beneficial effects for patients with NSCLC [12,64,65,66,67], and even more so for lung cancer patients harboring mutations in both TP53 and KRAS [68]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.